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Abstract
Many intracellular macromolecular complexes that are involved in 
the production or degradation of RNAs are targeted by auto­
antibodies in systemic autoimmune diseases. RNA interference 
(RNAi) is a recently characterized gene silencing pathway by which 
specific mRNAs are either degraded or translationally suppressed. 
In a recent issue of Arthritis  Research and Therapy, Andrew 
Jakymiw and colleagues reported that the enigmatic Su auto­
antigen complex contains key components of the RNAi machinery. 
Anti-Su autoantibodies from both human patients w ith rheumatic 
diseases and a mouse model o f autoimmunity recognize the endo­
nucleolytic Argonaute and D icer proteins, both crucial enzymes of 
the RNAi pathway. These data raise the question of how the anti­
Su response is triggered. So far, it is unknown whether molecular 
m odifications may be involved, as has been proposed for other 
intracellular autoantigens. The implication of RNAi in anti-viral 
defence may suggest a role for virus infection in th is process.
Many key regulators of gene expression were previously 
shown to be targeted by the immune system in a variety of 
autoimmune diseases. Patients w ith system ic autoimmune 
diseases com m only produce antibodies against specific  
classes of evolutionarily conserved nucleic acid-protein 
complexes. M ost frequently, the targeted proteins are either 
RNA-binding themselves or associated w ith RNA-binding 
proteins, rather than proteins associated w ith DNA. In many 
cases, the autoantibodies were used as a tool for the 
identification of the corresponding autoantigens and to 
characterize their structure and function [1]. Frequently, the 
prototypical autoantigens were designated w ith the first two 
characters of the patient's name in which autoantibodies 
against them were first detected. Examples are Sm, Ro, La, 
and Th/To, which represent autoantigenic targets associated 
w ith spliceosom al U small nuclear (sn) ribonucleoprotein 
particles (RNPs), the Y  RNA-containing Ro RNPs, the RNA- 
binding La protein, and the RNase MRP/RNase P endo- 
ribonucleases, respectively. These ribonucleoprotein particles 
accum ulate in different subcellu lar com partm ents and play
important roles in a variety of RNA m etabolic processes 
(Table 1) [2]. The recent w ork by Jakymiw and colleagues [3] 
shows that com ponents of the RNA interference machinery 
are also recognized by autoantibodies, referred to as anti-Su 
antibodies.
RNA interference (RNAi) is a recently identified mechanism 
by w h ich gene expression can be con tro lled post-transcrip - 
tionally [4]. RNAi is m ediated by small RNA m olecules, 21 
to 25 nucleotides in length, that guide prote in com plexes to 
com plem entary mRNA targets, whose expression is then 
silenced. These small RNAs can be either small interfering 
RNAs (siRNAs) or m icroRNAs (m iRNAs), w h ich derive from 
long doub le-stranded (ds)RNA and from  stem -loop 
s tructures in long, largely unstructured transcripts, 
respectively. The production  and function  of siR NAs and 
m iRNAs requires a com m on set of prote ins, includ ing a 
prote in called Dicer, w h ich acts as a dsR N A-specific  
endonuclease and is involved in the m aturation of these 
RNAs, and the fam ily of A rgonaute (Ago) prote ins, small 
RNA-binding, nucleo lytic enzymes m ediating the 
degradation of the targeted mRNA. A go  and the siRNA or 
m iRNA form  the core of the RN A-induced silencing com plex 
(RISC) [5].
The m olecular identity and biological function of the Su 
autoantigen remained elusive fo r many years. A  protein of 
about 10 0kD a  co-im m unoprecipitating w ith G W 1 82 , a 
recently identified protein required for RNAi, was hypothe­
sized by Jakymiw and colleagues [3] to be the Su auto­
antigen, which was known to migrate as a 1 0 0 /10 2  kDa 
doublet in SDS-PAG E [6]. Using a com bination of immuno- 
cytochem ical and im m unoprecipitation experiments, they 
dem onstrated that the Su autoantigen represents a 
macrom olecular complex associated w ith G W 1 8 2  and the 
RNAi pathway. The anti-Su autoimmune sera recognize
Ago =  Argonaute; ds =  double-stranded; miRNA =  microRNA; RISC =  RNA-induced silencing complex; RNAi =  RNA interference; siRNA =  small 
interfering RNA; RNP =  ribonucleoprotein particle.
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Tab le  1
Exam ples o f au toa n tig e n s  invo lved  in  RNA m e ta b o lic  processes
Autoantigen Ribonucleoprotein complex Target protein(s) Subcellular localization Process
Sm U snRNP Sm proteins Nucleoplasm Pre-mRNA splicing
Ro Y RNP Ro60 Cytoplasm RNA quality control
La La RNP La protein Nucleoplasm Maturation RNA Pol III transcripts
Th/To RNase MRP, RNase P Rpp38, Rpp25, Rpp20 Nucleoli Pre-rRNA processing
Su RISC Ago, Dicer Cytoplasm RNAi
RISC =  RNA-induced silencing complex; RNP =  ribonucleoprotein particle.
several members of the Ago protein family, which are known 
to associate into R ISC and which have a high degree of 
sequence identity. Targeting of the RNAi machinery by anti­
Su autoimmune sera was further supported by the 
identification of a 200 kDa protein associated w ith the Su 
antigenic complex as Dicer, the enzyme that converts dsRNA 
precursors into functional siRNAs and m iRNAs [5].
The disease specific ity of anti-Su antibodies has been 
addressed in only a few  studies so far. A lthough they were 
initially reported to be specifica lly associated w ith system ic 
lupus erythematosus [7], a later study showed that au to­
antibodies to the Su antigen are found in a variety of system ic 
rheumatic diseases [6]. The elucidation of the molecular 
identity of the Su antigen will facilitate the determ ination of 
the diagnostic and/or prognostic value of anti-Su antibodies.
W hy are so many protein and RNA-protein complexes that 
are involved in the synthesis, processing and degradation of 
various classes of RNA targeted by the immune system in 
system ic autoimmune diseases? One explanation m ight be 
that under certain circum stances (e.g., during cell death) 
relatively large amounts of these key com ponents of RNA 
m etabolic processes are chemically modified, escape from 
the cell (e.g., during necrosis) and are exposed to the immune 
system. The m olecular m odifications may be recognized as 
non-self and elicit a primary immune response in individuals 
w ith a ‘proper' genetic context. Environmental factors like 
trauma, drugs, irradiation or viruses may be responsible for a 
massive induction of cell death, either by apoptosis or 
(secondary) necrosis. Especially during programmed cell 
death, key regulators of gene expression are inactivated by 
proteolytic cleavage or other types of m odifications [8,9], 
most likely to prevent them from counteracting the execution 
of cell death. Via intra- and intermolecular epitope spreading, 
a primary immune response targeting the m odified antigen 
may spread to genuine autoantigenic epitopes, the recog­
nition of which does not require m olecular m odifications. The 
diversity of autoantibody specific ities and the ir association 
w ith particular diseases may be related to the com bination of 
genetic and environmental factors that are involved. This 
hypothesis is supported by several studies demonstrating
that the m olecular m odifications are essential fo r the early 
recognition by the immune system and that epitope 
spreading w ith autoantigenic prote ins/com plexes occurs in 
mammals [10-12].
This raises the question of whether a sim ilar mechanism may 
be involved in the anti-Su autoimmune response. Future 
studies will have to clarify whether one or more of the Ago 
and D icer proteins undergo m olecular changes in dying cells 
and, if so, whether the resulting neo-epitopes are recognized 
by early anti-Su sera.
Virus infections have been long associated w ith autoimmune 
diseases and various mechanisms im plicating viruses in the 
etio logy of these diseases have been proposed [13]. An 
intriguing aspect of autoimmune targeting of the RNAi 
machinery is that RNAi was initially recognized as an antiviral 
mechanism in plants and certain invertebrates [14]. The 
evolutionary conservation of RNAi suggests a sim ilar role for 
RNAi in mammals, which is indeed supported by the 
production of suppressors of RNAi by mammalian viruses 
[15]. Based upon these phenomena and additional evidence 
for the linkage of RNAi to virus-induced cellular events, 
Jakymiw and colleagues [3] argue that it is not surprising that 
the com ponents of the RNAi machinery develop into targets 
of autoimmunity. On the one hand, the induction of apoptosis 
as a result of the infection may lead to m olecular modification 
of host components, including A go and/or Dicer. On the 
other hand, the association of virus-like particles w ith 
com ponents of the RNAi machinery [16] may prom ote the 
development of autoimmunity.
Conclusion
The identification of com ponents of the RNAi machinery as 
targets of the anti-Su autoantibody system provides another 
example of an autoimmune response directed at a 
m acrom olecular complex that plays a key role in the post- 
transcriptional regulation of gene expression. Future studies 
will have to reveal how the generation of anti-Su 
autoantibodies is initiated, whether a viral factor is involved in 
this process, and whether testing fo r these autoantibodies is 
clinically relevant.
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